{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T07:56:23Z","timestamp":1780732583405,"version":"3.54.1"},"reference-count":33,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:00:00Z","timestamp":1732233600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"HepQuant, LLC"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Aims<\/jats:title>\n<jats:p>The dual oral cholate challenge test (DuO) quantifies liver function and portal-systemic shunting. Herein we report the economic impact of the use of the DuO Disease Severity Index (DSI) in the clinical management of patients with chronic liver disease suspected of having large esophageal varices.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>A Markov health state transition model of 100,000 patients with chronic liver disease suspected of having varices was populated with previously reported epidemiological, utility, and price data to assess the cost-effectiveness of employing the DuO test against the standard of care. The model examined the clinical and economic impact of healthcare management decisions all centered around the DSI score and given fixed prices of the DuO test.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>In the target population, the combined strategy of healthcare management decisions based on DSI results would be highly cost-effective within two years for a price of $3,250 per DuO test. These same management decisions would save 2,740 lives over five years. For a price of \u2264$3,213 per test, this intervention would be cost-saving within two years, and for \u2264$4,100 per test it would be cost-saving within five years.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Clinical decisions based on DSI from DuO are cost-effective in the management of patients with chronic liver disease suspected of having large esophageal varices. Future studies of direct comparison of DuO with other noninvasive tests are warranted. The DuO test offers a simplified approach that could enhance the clinical and research utility of liver function testing.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0313006","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T18:31:03Z","timestamp":1732300263000},"page":"e0313006","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cost-effectiveness of an oral cholate challenge test for the management of patients at risk for large esophageal varices"],"prefix":"10.1371","volume":"19","author":[{"given":"Shailesh","family":"Chavan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2126-9442","authenticated-orcid":true,"given":"Michael P.","family":"McRae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly R.","family":"Pitts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0454-3566","authenticated-orcid":true,"given":"Gregory T.","family":"Everson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,11,22]]},"reference":[{"key":"pone.0313006.ref001","first-page":"1","article-title":"Deaths: Final Data for 2020.","author":"KD Kochanek","year":"2023","journal-title":"National vital statistics reports: from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System."},{"issue":"7","key":"pone.0313006.ref002","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000062","article-title":"Increasing Economic Burden in Hospitalized Patients With Cirrhosis: Analysis of a National Database.","volume":"10","author":"AP Desai","year":"2019","journal-title":"Clin Transl Gastroenterol."},{"issue":"2","key":"pone.0313006.ref003","article-title":"Hospital Readmissions Among Patients With Decompensated Cirrhosis","volume":"107","author":"ML Volk","year":"2012","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"pone.0313006.ref004","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/hep.29887","article-title":"The high burden of alcoholic cirrhosis in privately insured persons in the United States","volume":"68","author":"JL Mellinger","year":"2018","journal-title":"Hepatology"},{"issue":"8","key":"pone.0313006.ref005","article-title":"Burden of Cirrhosis on Patients and Caregivers.","volume":"4","author":"ML Volk","year":"2020","journal-title":"Hepatol Commun."},{"issue":"6","key":"pone.0313006.ref006","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/s41575-023-00759-2","article-title":"Global epidemiology of cirrhosis\u2014aetiology, trends and predictions.","volume":"20","author":"DQ Huang","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"pone.0313006.ref007","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII\u2014Renewing consensus in portal hypertension","volume":"76","author":"R de Franchis","year":"2022","journal-title":"J Hepatol"},{"issue":"3","key":"pone.0313006.ref008","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/bcpt.13980","article-title":"Advances in noninvasive measurement of liver function and physiology: The HepQuant DuO test.","volume":"134","author":"MP McRae","year":"2024","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"2","key":"pone.0313006.ref009","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/apt.18054","article-title":"Liver function and portal-systemic shunting quantified by the oral cholate challenge test and risk for large oesophageal varices","volume":"60","author":"T Hassanein","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"pone.0313006.ref010","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.gastha.2024.07.005","article-title":"The Oral Cholate Challenge Test Quantifies Risk for Liver-Related Clinical Outcomes in Primary Sclerosing Cholangitis.","volume":"3","author":"S Helmke","year":"2024","journal-title":"Gastro Hep Advances."},{"issue":"10","key":"pone.0313006.ref011","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1097\/LVT.0000000000000420","article-title":"Hepatic improvement within 27 days of avenciguat treatment in Child-Pugh A cirrhosis detected by an oral cholate challenge test","volume":"30","author":"EJ Lawitz","year":"2024","journal-title":"Liver Transpl"},{"issue":"S1","key":"pone.0313006.ref012","article-title":"The next generation HepQuant tests measure reduction in risk for clinical events in compensated NASH cirrhosis subjects treated with resmetirom (abstract 2111-A).","volume":"78","author":"MP McRae","year":"2023","journal-title":"The Liver Meeting; October; Boston, Massachusetts: Hepatology"},{"issue":"2","key":"pone.0313006.ref013","article-title":"Hepatic functional improvement detected by HepQuant DuO within 120 days of treatment with rencofilstat (RCF) in MASH subjects with \u2265 F3 fibrosis (late breaking abstract 5032-C).","volume":"79","author":"MP McRae","year":"2024","journal-title":"The Liver Meeting; 2024; Boston, Massachusetts: Hepatology"},{"issue":"3","key":"pone.0313006.ref014","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1365-2036.2007.03389.x","article-title":"Portal-systemic shunting in patients with fibrosis or cirrhosis due to chronic hepatitis C: the minimal model for measuring cholate clearances and shunt","volume":"26","author":"GT Everson","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"pone.0313006.ref015","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/j.1365-2036.2008.03639.x","article-title":"The spectrum of hepatic functional impairment in compensated chronic hepatitis C: results from the Hepatitis C Anti-viral Long-term Treatment against Cirrhosis Trial","volume":"27","author":"GT Everson","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"pone.0313006.ref016","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/j.1365-2036.2008.03908.x","article-title":"Quantitative tests of liver function measure hepatic improvement after sustained virological response: results from the HALT-C trial","volume":"29","author":"GT Everson","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"pone.0313006.ref017","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/hep.24752","article-title":"Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: Results from the hepatitis C antiviral long-term treatment against cirrhosis trial","volume":"55","author":"GT Everson","year":"2012","journal-title":"Hepatology"},{"issue":"5","key":"pone.0313006.ref018","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.cct.2004.08.003","article-title":"Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders","volume":"25","author":"WM Lee","year":"2004","journal-title":"Control Clin Trials"},{"issue":"3","key":"pone.0313006.ref019","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1365-2893.2011.01563.x","article-title":"Economic burden of hepatitis C-associated diseases in the United States","volume":"19","author":"AC El Khoury","year":"2012","journal-title":"J Viral Hepat"},{"key":"pone.0313006.ref020","article-title":"Bloodwork Cost With and Without Insurance in","author":"J. Slobin","year":"2023"},{"key":"pone.0313006.ref021","unstructured":"Stempniak M. Diagnostic ultrasound cash price 308% higher than national average in one state [15 November 2023]. Available from: https:\/\/radiologybusiness.com\/topics\/medical-imaging\/ultrasound-imaging\/hospital-price-transparency-diagnostic-ultrasound-cost."},{"issue":"1","key":"pone.0313006.ref022","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jamainternmed.2015.6011","article-title":"Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population.","volume":"176","author":"HS Chahal","year":"2016","journal-title":"JAMA Intern Med"},{"key":"pone.0313006.ref023","doi-asserted-by":"crossref","first-page":"e890","DOI":"10.1016\/j.cgh.2021.04.030","article-title":"HepQuant SHUNT Detects Portal Hypertension in Early Stages of Clinically Compensated Chronic Liver Disease","volume":"20","author":"A Wieland","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"pone.0313006.ref024","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/MOG.0000000000000167","article-title":"Noninvasive assessment of liver function","volume":"31","author":"S Helmke","year":"2015","journal-title":"Curr Opin Gastroenterol"},{"issue":"7","key":"pone.0313006.ref025","doi-asserted-by":"crossref","first-page":"S","DOI":"10.1016\/S0016-5085(22)63507-8","article-title":"The HepQuant SHUNT Disease Severity Index (HepQuant DSI) can aid the decision to avoid endoscopic screening or surveillance for varices needing treatment (abstract).","volume":"162","author":"ML Shiffman","year":"2022","journal-title":"Gastroenterology"},{"issue":"S1","key":"pone.0313006.ref026","first-page":"1264A","article-title":"The HepQuant SHUNT Test predicts the likelihood of finding esophageal varices and particularly large varices at endoscopy (abstract).","volume":"74","author":"ML Shiffman","year":"2021","journal-title":"Hepatology"},{"issue":"2","key":"pone.0313006.ref027","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/lt.500030210","article-title":"Quantitative liver function tests define the functional severity of liver disease in early-stage cirrhosis","volume":"3","author":"R Shrestha","year":"1997","journal-title":"Liver Transpl Surg"},{"issue":"8","key":"pone.0313006.ref028","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/apt.16283","article-title":"Predicting clinical decompensation in patients with cirrhosis using the HepQuant SHUNT test","volume":"53","author":"MA Fallahzadeh","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"pone.0313006.ref029","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.trsl.2020.12.010","article-title":"The within-individual reproducibility of the disease severity index from the HepQuant SHUNT test of liver function and physiology","volume":"233","author":"JR Burton","year":"2021","journal-title":"Transl Res"},{"issue":"4","key":"pone.0313006.ref030","doi-asserted-by":"crossref","first-page":"e13786","DOI":"10.1111\/cts.13786","article-title":"Within individual reproducibility of a dual sample oral cholate challenge test (DuO) and other simplified versions of the HepQuant test.","volume":"17","author":"MP McRae","year":"2024","journal-title":"Clin Transl Sci"},{"key":"pone.0313006.ref031","article-title":"editors. Effect of obeticholic acid on liver function in patients with fibrosis due to NASH [Abstract]","author":"N Alkhouri","year":"2019","journal-title":"J Hepatol"},{"issue":"11","key":"pone.0313006.ref032","doi-asserted-by":"crossref","first-page":"e0276","DOI":"10.1097\/HC9.0000000000000276","article-title":"Safety and pharmacokinetics of BI 685509, a soluble guanylyl cyclase activator, in patients with cirrhosis: A randomized Phase Ib study.","volume":"7","author":"EJ Lawitz","year":"2023","journal-title":"Hepatol Commun."},{"key":"pone.0313006.ref033","article-title":"AASLD Practice Guideline on noninvasive liver disease assessment of portal hypertension","author":"RK Sterling","year":"2024","journal-title":"Hepatology"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0313006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T18:31:19Z","timestamp":1732300279000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0313006"}},"subtitle":[],"editor":[{"given":"Rudolf E.","family":"Stauber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,11,22]]},"references-count":33,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0313006","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,22]]}}}